News

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks